RenovoRx Inc.
Delivering diagnostic and therapeutic fluids directly to the pancreas
This article was originally published in Start Up
Executive Summary
Pancreatic cancer is currently the fourth leading cause of cancer death in the US, and it is primarily treated with systemic drugs that have limited ability to penetrate the pancreas. RenovoRx Inc. has developed an endovascular catheter that enables targeted delivery of either diagnostic or therapeutic fluids directly to the pancreas.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.